Clinical course and prognosis of non-secretory multiple myeloma

European Journal of Haematology

Volumn 95, Issue 1, 2015, Pages 57-64

  Chawla, Sagar S ^a   Kumar, Shaji K ^b   Dispenzieri, Angela ^b   Greenberg, Alexandra J ^b   Larson, Dirk R ^b   Kyle, Robert A ^b   Lacy, Martha Q ^b   Gertz, Morie A ^b   Rajkumar, S Vincent ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Myeloma; Prognosis; Therapy

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CALCIUM; CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOMODULATING AGENT; M PROTEIN; MONOCLONAL PROTEIN; PREDNISONE; PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; PARAPROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NON SECRETORY MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; SYSTEMIC THERAPY; TIME TO TREATMENT; TREATMENT RESPONSE; BLOOD; GENE EXPRESSION; GENETICS; MORTALITY; SECRETION (PROCESS); SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84931571439     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12478     Document Type: Article

References (23)

1. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:225-35.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1, 027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003;78:21-33.
4. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999;13:1259-72.
5. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
6. Lonial S, Kaufman JL. Non-secretory myeloma: a clinician's guide. Oncology 2013;27:924-8, 30.
7. Dreicer R, Alexanian R. Nonsecretory multiple myeloma. Am J Hematol 1982;13:313-8.
8. Cavo M, Galieni P, Gobbi M, Baldrati L, Leardini L, Baccarani M, Tura S. Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol 1985;74:27-30.
9. Smith DB, Harris M, Gowland E, Chang J, Scarffe JH. Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol 1986;4:307-13.
10. Decourt C, Galea HR, Sirac C, Cogne M. Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias. J Leukoc Biol 2004;76:528-36.
11. Mancilla R, Davis GL. Nonsecretory multiple myeloma. Immunohistologic and ultrastructural observations on two patients. Am J Med 1977;63:1015-22.
12. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003;101:1570-1.
13. Bourantas K. Nonsecretory multiple myeloma. Eur J Haematol 1996;56:109-11.
14. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2013;28:1122-8.
15. Kumar S, Perez WS, Zhang MJ, et al. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2008;14:1134-40.
16. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 2003;31:163-70.
17. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
18. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
19. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2.
20. Snozek CLH, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the International Staging System. Leukemia 2008;22:1933-7.
21. Dimopoulos MA, Kastritis E, Terpos E. Non-secretory myeloma: one, two, or more entities? Oncology 2013;27:930-2.
22. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
23. Fonseca R. Non-secretory myeloma: clinical and biologic implications. Oncology 2013;27:932-3.